Condition
Chronic Kidney Disease Stages 3-5
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 2 (1)
Trial Status
Not Yet Recruiting1
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06948292Phase 2CompletedPrimary
Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics
NCT06677021Not ApplicableNot Yet RecruitingPrimary
Understanding Physical Activity and Quality of Life in Children and Young People with Chronic Kidney Disease
NCT01263028Not ApplicableTerminatedPrimary
Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose
Showing all 3 trials